Cargando…
TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252355/ http://dx.doi.org/10.1016/S0168-8278(22)01748-2 |
| _version_ | 1784740245080637440 |
|---|---|
| author | Lawitz, Eric Loomba, Rohit Denham, Douglas Chung, Diana Quirk, Erin Lee, Lois Marmon, Tonya Kowdley, Kris |
| author_facet | Lawitz, Eric Loomba, Rohit Denham, Douglas Chung, Diana Quirk, Erin Lee, Lois Marmon, Tonya Kowdley, Kris |
| author_sort | Lawitz, Eric |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9252355 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Association for the Study of the Liver. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92523552022-07-05 TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study Lawitz, Eric Loomba, Rohit Denham, Douglas Chung, Diana Quirk, Erin Lee, Lois Marmon, Tonya Kowdley, Kris J Hepatol POSTER PRESENTATIONS: Saturday 25 June: NAFLD: Therapy European Association for the Study of the Liver. Published by Elsevier B.V. 2022-07 2022-07-04 /pmc/articles/PMC9252355/ http://dx.doi.org/10.1016/S0168-8278(22)01748-2 Text en Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | POSTER PRESENTATIONS: Saturday 25 June: NAFLD: Therapy Lawitz, Eric Loomba, Rohit Denham, Douglas Chung, Diana Quirk, Erin Lee, Lois Marmon, Tonya Kowdley, Kris TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study |
| title | TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study |
| title_full | TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study |
| title_fullStr | TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study |
| title_full_unstemmed | TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study |
| title_short | TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study |
| title_sort | tern-101, a farnesoid x receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (covid-19) exposure compared to those with no covid-19 exposure in phase 2a lift study |
| topic | POSTER PRESENTATIONS: Saturday 25 June: NAFLD: Therapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252355/ http://dx.doi.org/10.1016/S0168-8278(22)01748-2 |
| work_keys_str_mv | AT lawitzeric tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT loombarohit tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT denhamdouglas tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT chungdiana tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT quirkerin tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT leelois tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT marmontonya tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy AT kowdleykris tern101afarnesoidxreceptoragonistdemonstratedsimilarsafetyandefficacyinnonalcoholicsteatohepatitispatientswithcoronavirusdiseaseof2019covid19exposurecomparedtothosewithnocovid19exposureinphase2aliftstudy |